 |
 |
|||||||||||||||
 |
||||||||||||||||
|
||||||||||||||||
|
||||||||||||||||
|
Phase 2 Intravenous Administration In Combination With Paclitaxel and Carboplatin In Patients With Non-Small Cell Lung Cancer Oncolytics announced in March 2009 that it had started patient enrolment in its U.S. Phase 2 clinical trial using intravenous administration of REOLYSIN® in combination with paclitaxel and carboplatin in patients with non-small cell lung cancer (NSCLC) with K-RAS or EGFR-activated tumours. The primary objectives of the Phase 2 trial are to determine the objective response rate of REOLYSIN® in combination with paclitaxel and carboplatin in patients with metastatic or recurrent NSCLC with K-RAS or EGFR-activated tumours, and to measure progression-free survival at 6 months. The secondary objectives are to determine the median survival and duration of progression-free survival in patients, and to evaluate the safety and tolerability of REOLYSIN® in combination with paclitaxel and carboplatin in this patient population. See related press releases and documents: July 6, 2011 - Oncolytics Biotech® Inc. Collaborators Present Positive REOLYSIN® Clinical Trial Results at the 14th World Conference on Lung Cancer Mar 12, 2009 - Oncolytics Biotech® Inc. Announces Start of Enrolment in U.S. Phase 2 Combination Clinical Trial for Non-Small Cell Lung Cancer Patients with K-RAS or EGFR-Activated Tumours Sept 2, 2008 - Oncolytics Biotech Inc. Announces U.S. Phase 2 Combination Clinical Trial for Non-Small Cell Lung Cancer Patients with K-RAS or EGFR-Activated Tumours |
|
|||||||||||
 |
|
 |